OTC · IMVIF
IMV Inc.
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · TAISF · USD
Stock price, dividends, earnings
Quote as of Jan 3, 2024, 02:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Taisho Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 1.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Taisho Pharmaceutical Holdings Co., Ltd.’s forward annual dividend is $0.67 per share, paid semi-annual. The forward yield is 1.13% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Taisho Pharmaceutical Holdings Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Taisho Pharmaceutical Holdings Co., Ltd., headquartered in Tokyo, Japan, is a long-established global pharmaceutical company, founded in 1912. The company and its subsidiaries are comprehensively involved in the research, development, manufacturing, marketing, and distribution of both over-the-counter (OTC) consumer health products and prescription pharmaceuticals, serving markets within Japan and around the world. Its operations are distinctly organized into two primary divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Operation Group concentrates on consumer health products. This segment provides a diverse array of OTC drugs, quasi-drugs, nutritional items, and general health and hygiene supplies. Key brands include the Lipovitan range of energy drinks, Pabron for cold and sinus relief, RiUP hair regrowth treatments, Taisho Kampo for digestive health, Colac laxatives, Naron and other products for pain and fever relief (antipyretic analgesics), Preser hemorrhoid treatments, and internationally recognized brands such as Hapacol, Efferalgan, Dafalgan, and Tempra (also antipyretic analgesics), Counterpain topical anti-inflammatory analgesics, Vitacilina for dermatological care, and VICKS cough suppressants and medicated drops. Beyond its pharmaceutical offerings, this division also has ventures in real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Operation Group focuses on ethical drugs. Its portfolio features medications like Edirol (an active vitamin D3 agent for osteoporosis), Clarith (a macrolide antibiotic), Palux (a peripheral vasodilator), Bonviva (a bisphosphonate osteoporosis agent), Lusefi (for type 2 diabetes mellitus), and LOQOA (a transdermal anti-inflammatory analgesic). This segment maintains an active research pipeline, with numerous products currently under development, primarily targeting therapeutic areas such as central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials essential for pharmaceuticals and quasi-drugs, alongside offering a range of health foods and skincare items.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:47 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| $521.13M-0.11% vs estimate |
| Q1 2023 | Aug 3, 2022 | $0.52-98.8% vs estimate | $508.62M+3.17% vs estimate |
|---|
| Q4 2022 | May 13, 2022 | $0.51+51.06% vs estimate | $559.87M-4.08% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.00 (-50.0%)
The Greenrose Holding Company Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00-$0.00 (-99.0%)
Mountain High Acquisitions Corp.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00+$0.00 (+40,113.65%)
Indie Ranch Media, Inc.: Healthcare · Medical - Care Facilities.
$0.00-$0.00 (-99.0%)
Allena Pharmaceuticals, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
TGC Ventures International, Inc.: Healthcare · Medical - Distribution.
$0.00$0.00 (0.0%)
Photoelectron Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
ReGen Biologics Inc.: Healthcare · Medical - Instruments & Supplies.
